Business and Finance

CVS Caremark, Express Scripts, OptumRx made more than $7.3 billion in revenue, with markups as high as thousands of percent.

Cryoport's business unit, Cryogene, will be tasked with helping to foster the growth of Moffitt’s cell and gene therapy efforts.

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

The deal is expected to be finalized by the first half of this year.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations.

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

Why well-organized documentation is critical at every stage of the process.

The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, details the types of regulatory pressures and factors surrounding rising R&D costs that will affect the pharmaceutical industry.

The 50,000 square-foot plant is expected to augment the compounding and fulfillment experience for telehealth companies.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, describes how events such as the East and Gulf Coast port strikes have brought to light the differences between branded and generic pharmaceuticals.

Tips for pharmacies with the reimbursement blues.

Digital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.

Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.

Albert Thigpen, co-founder, Talentwise Consulting, explains how the specialty pharmacy sector has evolved over the years.

Are SDOHs associated with Medicare, Medicaid, and private insurer spending?

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

The offering will become available in 49 states by next year.

A panel dives into the current and future outlook of healthcare policies.

Session dives into how healthcare policy implementation impacts stakeholders long-term.

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.